ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer December 6, 2025 8:00 PM EST
Company Participants
Dominic Piscitelli – Chief Financial Officer
Jacob Chacko – President, CEO & Director
Lori Friedman – Chief Scientific Officer
Pratik Multani – Chief Medical Officer
Conference Call Participants
Anupam Rama – JPMorgan Chase & Co, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Maurice Raycroft – Jefferies LLC, Research Division
Bradley Canino – Guggenheim Securities, LLC, Research Division
Colleen Hanley – Robert W. Baird & Co. Incorporated, Research Division
Derek Archila – Wells Fargo Securities, LLC, Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the ORIC Enozertinib Program Update Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your first speaker, Dominic Piscitelli, Chief Financial Officer. Please go ahead.
Dominic Piscitelli
Chief Financial Officer
Good morning from Singapore, and welcome to the ORIC Pharmaceuticals Enozertinib Program Update Conference Call. Earlier this week, we issued multiple press releases highlighting updated data from our ongoing Phase Ib study of Enozertinib in non-small cell lung cancer patients. You may find the press release is posted on the investor page of oricpharma.com. We have prerecorded our prepared remarks, after which we will host a live Q&A session. .
Before we begin, during this call, we will be making forward-looking statements, including forward-looking statements based on our current expectations and projections about future events. Our actual results may differ materially from those indicated by such forward-looking statements. For a description of risk factors, please refer to our recent filings with the SEC. ORIC specifically disclaims any obligation to update any forward-looking statements.
